LAS VEGAS, NV ├ó Oct. 30, 2013 - (CRWE Press Release) ├ó Broadleaf Capital Partners, Inc. (OTCMKTS:BDLF) and Sustained Release, Inc. (SRI) have agreed to terms and conditions under which Broadleaf will acquire Sustained Release, Inc. The agreement is scheduled to become ef
Online PR News – 31-October-2013 – Las Vegas, NV – LAS VEGAS, NV ├ó Oct. 30, 2013 - (CRWE Press Release) ├ó Broadleaf Capital Partners, Inc. (OTCMKTS:BDLF) and Sustained Release, Inc. (SRI) have agreed to terms and conditions under which Broadleaf will acquire Sustained Release, Inc. The agreement is scheduled to become effective on or before December 1, 2013. Mike King, President of Broadleaf, stated: ├óThis acquisition is exciting because Sustained Release brings to us a contract with Akina, Inc. relating to extended drug delivery systems. This patent protected technology will provide much needed dynamic benefits to the pharmaceutical sector and will also dramatically improve our shareholder value.├ó┬Ł Akina, Inc. is a research and development company known for developing unique methods for delivering medications. It was founded in 2001 by Kinam Park, Showalter Distinguished Professor of Biomedical Engineering and Professor of Pharmaceutics at Purdue University. Akina Is a pioneer in the development of the long-term release micro particle formulations, also referenced as ├óSustained Release Formulations├ó┬Ł, which have release durations ranging from one to eight months, and are -designed to replace repeated daily, weekly or monthly administration of drugs for long-term care of diseases and disorders, thereby higher efficacy of the drug. The Akina micro particles are programmable in release kinetics and ideal for release of active pharmaceutical ingredients for terms ranging from a few weeks to several months. They are inexpensive to produce, readily scalable for mass production, and offer a wide range of clinical applications. Examples of current micro particle formulations under development at Akina address specific conditions such as macular degeneration, glaucoma, periodontal disease, and inflammation. Akina├ós hydrogel template method is highly unique in that the process does not include oil/water emulsion, and thus it allows controlled manipulation of the drug/polymer formulation which has not been possible by other methods. About Broadleaf Capital Partners: Broadleaf Capital Partners Inc. Inc. (OTCMKTS:BDLF) actively identifies and reviews unique and proprietary technologies for investment consideration. Broadleaf seeks such technologies held by emerging or early stage, small to medium-size companies in various fields of business to arrange for capital and provide management support. Our goal is to provide our stockholders capital appreciation and a solid dividend yield. Learn more about Broadleaf at: www.bdlfpartners.com This press release includes ├óforward-looking statements├ó┬Ł within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms ├óbelieves,├ó┬Ł ├óbelief,├ó┬Ł ├óexpects,├ó┬Ł ├óintends,├ó┬Ł ├óanticipates,├ó┬Ł ├ówill,├ó┬Ł or ├óplans├ó┬Ł to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company├ós reports and registration statements filed with the Securities and Exchange Commission. Contact Princeton Research, Inc., Las Vegas Mike King, 702-650-3000 email@example.com Source: Broadleaf Capital Partners Inc.